Johnson & Johnson (JNJ) Stock Gets Fair Value Bump On Mixed Analyst Target Changes

Johnson & Johnson’s implied fair value has been adjusted from US$270.59 to US$279.41 per share, reflecting a modest reset in price targets around the stock. Recent research shows a split view, with more positive analysts pointing to earnings resilience and the drug pipeline, while cautious voices highlight valuation, MedTech execution risk, and potential earnings dilution from recent deals. In the sections that follow, you will see how these shifting targets and narratives fit together and...